Approaching clinical proteomics: Current state and future fields of application in cellular proteomics
Authors: Apweiler Rolf , Aslanidis Charalampos , Deufel Thomas , Gerstner Andreas , Hansen Jens , Hochstrasser Dennis , Kellner Roland , Kubicek Markus , Lottspeich Friedrich , Maser Edmund , Mewes Hans‐Werner , Meyer Helmut E. , Müllner Stefan , Mutter Wolfgang , Neumaier Michael , Nollau Peter , Nothwang Hans G. , Ponten Fredrik , Radbruch Andreas , Reinert Knut , Rothe Gregor , Stockinger Hannes , Tárnok Attila , Taussig Mike J. , Thiel Andreas , Thiery Joachim , Ueffing Marius , Valet Günther , Vandekerckhove Joel , Wagener Christoph , Wagner Oswald , Schmitz Gerd 
Published: September 2009

Recent developments in proteomics technology offer new opportunities for clinical applications in hospital or specialized laboratories including the identification of novel biomarkers, monitoring of disease, detecting adverse effects of drugs, and environmental hazards. Advanced spectrometry technologies and the development of new protein array formats have brought these analyses to a standard, which now has the potential to be used in clinical diagnostics. Besides standardization of methodologies and distribution of proteomic data into public databases, the nature of the human body fluid proteome with its high dynamic range in protein concentrations, its quantitation problems, and its extreme complexity present enormous challenges. Molecular cell biology (cytomics) with its link to proteomics is a new fast moving scientific field, which addresses functional cell analysis and bioinformatic approaches to search for novel cellular proteomic biomarkers or their release products into body fluids that provide better insight into the enormous biocomplexity of disease processes and are suitable for patient stratification, therapeutic monitoring, and prediction of prognosis. Experience from studies of in vitro diagnostics and especially in clinical chemistry showed that the majority of errors occurs in the preanalytical phase and the setup of the diagnostic strategy. This is also true for clinical proteomics where similar preanalytical variables such as inter‐ and intra‐assay variability due to biological variations or proteolytical activities in the sample will most likely also influence the results of proteomics studies. However, before complex proteomic analysis can be introduced at a broader level into the clinic, standardization of the preanalytical phase including patient preparation, sample collection, sample preparation, sample storage, measurement, and data analysis is another issue which has to be improved. In this report, we discuss the recent advances and applications that fulfill the criteria for clinical proteomics with the focus on cellular proteomics (cytoproteomics) as related to preanalytical and analytical standardization and to quality control measures required for effective implementation of these technologies and analytes into routine laboratory testing to generate novel actionable health information. It will then be crucial to design and carry out clinical studies that can eventually identify novel clinical diagnostic strategies based on these techniques and validate their impact on clinical decision making. © 2009 International Society for Advancement of Cytometry